首页> 外文期刊>Blood cancer journal. >Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
【24h】

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts

机译:外泌体通过靶向破骨细胞和成骨细胞在多发性骨髓瘤骨病和肿瘤发展中发挥作用

获取原文
           

摘要

Progression of multiple myeloma (MM) is largely dependent on the bone marrow (BM) microenvironment wherein communication through different factors including extracellular vesicles takes place. This cross-talk not only leads to drug resistance but also to the development of osteolysis. Targeting vesicle secretion could therefore simultaneously ameliorate drug response and bone disease. In this paper, we examined the effects of MM exosomes on different aspects of osteolysis using the 5TGM1 murine model. We found that 5TGM1 sEVs, or ‘exosomes’, not only enhanced osteoclast activity, they also blocked osteoblast differentiation and functionality in vitro. Mechanistically, we could demonstrate that transfer of DKK-1 led to a reduction in Runx2, Osterix, and Collagen 1A1 in osteoblasts. In vivo, we uncovered that 5TGM1 exosomes could induce osteolysis in a similar pattern as the MM cells themselves. Blocking exosome secretion using the sphingomyelinase inhibitor GW4869 not only increased cortical bone volume, but also it sensitized the myeloma cells to bortezomib, leading to a strong anti-tumor response when GW4869 and bortezomib were combined. Altogether, our results indicate an important role for exosomes in the BM microenvironment and suggest a novel therapeutic target for anti-myeloma therapy.
机译:多发性骨髓瘤(MM)的进展在很大程度上取决于骨髓(BM)微环境,其中通过包括细胞外囊泡在内的不同因素进行交流。这种串扰不仅导致耐药性,而且导致骨溶解的发展。因此,靶向囊泡分泌可以同时改善药物反应和骨骼疾病。在本文中,我们使用5TGM1小鼠模型研究了MM外泌体对溶骨不同方面的影响。我们发现5TGM1 sEV或“外来体”不仅增强了破骨细胞的活性,而且还阻断了体外的成骨细胞分化和功能。从机制上讲,我们可以证明DKK-1的转移导致成骨细胞中Runx2,Osterix和胶原1A1的减少。在体内,我们发现5TGM1外泌体可能以与MM细胞本身相似的模式诱导骨溶解。使用鞘磷脂酶抑制剂GW4869阻止外泌体分泌不仅增加了皮质骨的体积,而且还使骨髓瘤细胞对硼替佐米敏感,导致当GW4869和硼替佐米联合使用时产生强烈的抗肿瘤反应。总之,我们的结果表明外泌体在BM微环境中具有重要作用,并提出了抗骨髓瘤治疗的新型治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号